A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC.

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

August 30, 2026

Conditions

EGFR-mutated Locally Advanced or Metastatic NSCLC

Interventions

DRUG

SYS6010

SYS6010,Q3W

DRUG

Pemetrexed

Pemetrexed injection 500 mg/m\^2 administered via intravenous infusion，Q3W

DRUG

Cisplatin

Cisplatin 75 mg/m\^2 administered via intravenous infusion，Q3W

DRUG

Carboplatin

Carboplatin (AUC=5, Calvert formula) administered via intravenous infusion，Q3W

All Listed Sponsors

lead

CSPC Megalith Biopharmaceutical Co.,Ltd.

INDUSTRY

NCT06927986 - A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC. | Biotech Hunter | Biotech Hunter